Biotechnology

Filter

Current filters:

None

Popular Filters

1976 to 2000 of 2322 results

Amylin operating loss leaps to over $30 million

27-04-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq AMLN): reported financial results for the quarter ended…

AmylinBiotechnologyFinancialMergers & Acquisitions

Amgen acquires Turkish drugmaker Mustafa Nevzat for $700 million

26-04-2012

Global biotech giant Amgen (Nasdaq: AMGN) has reached agreement to acquire 95.6% of Mustafa Nevzat Pharmaceuticals…

AmgenBiotechnologyMergers & AcquisitionsMustafa Nevzat PharmaPharmaceutical

Positive Ph III data for Biogen Idec's oral MS drug candidate BG-12

25-04-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) says that detailed positive data from CONFIRM, the second…

Biogen IdecBiotechnologydimethyl fumarateNeurologicalResearch

Amgen beats forecasts as EPS leaps more than 20%

25-04-2012

USA-based Amgen (Nasdaq: AMGN), the world's biggest independent biotech company, posted strong first-quarter…

AmgenBiotechnologyFinancial

GSK takeover target Human Genome sees 4th-qtr loss narrow

25-04-2012

Human Genome Sciences (Nasdaq: HGSI), the subject of a $2.59 billion hostile takeover bid from the UK's…

BenlystaBiotechnologyFinancialHuman Genome Sciences

Merck KGaA to rationalize operations in Switzerland

24-04-2012

German drug major Merck KGaA (MRK: DE) has announced efficiency measures it plans to take related to…

BiotechnologyManagementMerck KGaAMerck SeronoPharmaceuticalResearch

Vaccines collaborations by Biovest and US Army and by ARTES and Crucell

24-04-2012

USA-based Biovest International (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals…

ARTES BiotechnologyBiotechnologyBiovest InternationalCrucellJohnson & JohnsonResearchVaccines

Biota and Nabi announce proposed merger

24-04-2012

Australian firm Biota Holdings (ASX: BTA) and USA-based Nabi Biopharmaceuticals (Nasdaq: NABI) yesterday…

Biota HoldingsBiota PharmaceuticalsBiotechnologyMergers & AcquisitionsNabi BiopharmaceuticalsPharmaceutical

PhRMA firms have nearly 300 therapeutic vaccines in development

23-04-2012

US research-based biopharmaceutical companies are developing nearly 300 vaccines for the prevention and…

BiotechnologyNorth AmericaPharmaceuticalResearchVaccines

FDA strengthens monitoring of post-approval drug safety

23-04-2012

In what is seen as a response to criticism that the agency lacks teeth in monitoring drugs once they…

BiotechnologyMarkets & MarketingNorth AmericaPharmaceuticalRegulation

Human Genome rejects unsolicited takeover bid from GlaxoSmithKline

20-04-2012

US drugmaker Human Genome Sciences (Nasdaq: HGSI) revealed yesterday that it has rejected an unsolicited…

BiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Cell Therapeutics to acquire pacritinib, a potential myelofibrosis drug

20-04-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) and Singapore-based S*BIO Pte have entered into…

BiotechnologyCell TherapeuticsImmunologicalsLicensingOncologypacritinibS*BIO

Crucial need for global development of biosimilars, says head of European generics group

20-04-2012

"The need for a framework which allows global biosimilars development is now crucial," argued European…

BiotechnologyGenericsGlobalRegulation

US Senators Burr and Coburn introduce legislation to reform FDA

19-04-2012

US Senators Richard Burr (Republican, North Carolina) and Tom Coburn (Republican, Oklahoma) this week…

BiotechnologyLegalNorth AmericaPharmaceuticalPoliticsRegulation

Adimab enters new antibody discovery programs

19-04-2012

Therapeutic antibody developer Adimab says that it has initiated two new independent research collaborations.…

AdimabBiotechnologyGilead SciencesResearch

Roche will not extend its tender offer for Illumina

19-04-2012

In view of the apparent re-election of the incumbent directors of Illumina (Nasdaq: ILMN), a leading…

BiotechnologyIlluminaMergers & AcquisitionsPharmaceuticalRoche

Actelion 1st-qtr profits slump as lead product sales slip

19-04-2012

Switzerland-based Actelion (ATLN: VX), Europe's largest biotech firm, posted first-quarter 2012 financial…

ActelionBiotechnologyFinancial

Health activists call for greater public return on EU health R&D spending and a turn to needs-driven innovation

18-04-2012

In a Policy Paper published yesterday, Health Action International (HAI) Europe and the Trans Atlantic…

BiotechnologyEuropeFinancialPharmaceuticalResearch

Australian Biotech industry confident, despite economic woes

18-04-2012

The annual Biotechnology Industry Position Survey shows the bullish sentiment for the Australian industry's…

Asia-PacificBiotechnologyFinancialResearch

Towards a robust global framework for conduct and oversight of clinical trials in EU

18-04-2012

The European Medicines Agency has published the final reflection paper on ethical and good clinical practice…

BiotechnologyEuropePharmaceuticalRegulationResearch

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan

17-04-2012

Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

ImmunoGen IND for IMGN853 now active; IMGN529 trial commenced

17-04-2012

US biotechnology firm ImmunoGen (Nasdaq: IMGN) says that the Investigational New Drug (IND) application…

BiotechnologyImmunoGenOncologyResearch

1976 to 2000 of 2322 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top